Biotech Values

[apljack]

EYEN Stock here has been experiencing a technical breakout from a recent low of $2.66 to today's current $4.13. 3 days of 6-10X volume on no official news except from two weeks ago when they announced that they were re-starting their atropine study enrollment for progressive myopia in children. This had been halted secondary to COVID issues. In the background, the company had reported their expectation to file the NDA for Mydriasis indication in 2H 2020 for in-clinic dilations.

The nice under-the-radar aspect of this company is that all of their treatments come with their patented piezo-electric microdosing system, the first real advancement of administration since the invention of the eye dropper. There is no news/information on pricing of the device.

Keep an eye on this company, shared issues are low and the float is low, news may move it in big steps.

AJ